colistinmethanesulfonic acid
(IQWHCHZFYPIVRV-UHFFFAOYSA-I)
Structure
- SMILES
- CCC(CCCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC1CCNC(=O)C(NC(=O)C(CCNCS(=O)(=O)[O-])NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CCNCS(=O)(=O)[O-])CC(C)C)CC(C)C)CCNCS(=O)(=O)[O-])C(O)C)CCNCS(=O)(=O)[O-])C(O)C)CCNCS(=O)(=O)[O-])C.[Na+].[Na+].[Na+].[Na+].[Na+]
- Molecular Formula:
- C58H105N16Na5O28S5
- Molecular Weight:
- 1749.820
- Log P:
- 1.4503
- Hydrogen Bond Acceptor:
- 44
- Hydrogen Bond Donor:
- 18
- TPSA:
- 748.61
- CAS Number(s):
- 12705-41-8
Synonym(s)
1.
colistinmethanesulfonic acid
2.
colistimethate
3.
colistimethate sodium
4.
colistimethate, disodium salt
5.
colistin sodium methanesulfonate
External Link(s)
Adverse Drug Event(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Blood creatinine increased | FAERS: 4 | US FAERS | |
| 2 | Blood urea increased | FAERS: 3 Canada Vigilance: 3 | Canada Vigilance US FAERS | |
| 3 | Pneumonia | FAERS: 3 | US FAERS | |
| 4 | Acute kidney injury | FAERS: 2 | 5142051 5419940 | CTD US FAERS |
| 5 | Acute respiratory failure | FAERS: 2 | US FAERS | |
| 6 | Dizziness | FAERS: 2 Canada Vigilance: 5 | Canada Vigilance US FAERS | |
| 7 | Infection | FAERS: 2 | US FAERS | |
| 8 | Infective pulmonary exacerbation of cystic fibrosis | FAERS: 2 | US FAERS | |
| 9 | Medication Error | FAERS: 2 | US FAERS | |
| 10 | Product dispensing error | FAERS: 2 | US FAERS | |
| 11 | Respiratory distress | FAERS: 2 | US FAERS | |
| 12 | Septic Shock | FAERS: 2 | US FAERS | |
| 13 | Tracheobronchitis | FAERS: 2 | US FAERS | |
| 14 | Alopecia | FAERS: 1 | US FAERS | |
| 15 | Asthenia | FAERS: 1 | US FAERS | |
| 16 | Chest discomfort | FAERS: 1 | US FAERS | |
| 17 | Creatinine renal clearance decreased | FAERS: 1 | US FAERS | |
| 18 | Deafness | FAERS: 1 | US FAERS | |
| 19 | Disease Progression | FAERS: 1 | US FAERS | |
| 20 | Disease complication | FAERS: 1 | US FAERS | |
| 21 | Endocarditis | FAERS: 1 | US FAERS | |
| 22 | Incorrect route of product administration | FAERS: 1 | US FAERS | |
| 23 | Increased bronchial secretion | FAERS: 1 | US FAERS | |
| 24 | Intentional product use issue | FAERS: 1 | US FAERS | |
| 25 | Klebsiella sepsis | FAERS: 1 | US FAERS | |
| 26 | Malaise | FAERS: 1 | US FAERS | |
| 27 | Mental status changes | FAERS: 1 | US FAERS | |
| 28 | Pancreatitis | FAERS: 1 | US FAERS | |
| 29 | Product reconstitution quality issue | FAERS: 1 | US FAERS | |
| 30 | Product use issue | FAERS: 1 | US FAERS | |
| 31 | Productive Cough | FAERS: 1 | US FAERS | |
| 32 | Pruritus | FAERS: 1 Canada Vigilance: 6 | Canada Vigilance US FAERS | |
| 33 | Pulmonary Fibrosis | FAERS: 1 | US FAERS | |
| 34 | Quadriparesis | FAERS: 1 | US FAERS | |
| 35 | Respiratory Failure | FAERS: 1 | US FAERS | |
| 36 | Rhabdomyolysis | FAERS: 1 | US FAERS | |
| 37 | Sepsis | FAERS: 1 | US FAERS | |
| 38 | Stenotrophomonas test positive | FAERS: 1 | US FAERS | |
| 39 | Syncope | FAERS: 1 | US FAERS | |
| 40 | Therapy cessation | FAERS: 1 | US FAERS | |
| 41 | Therapy change | FAERS: 1 | US FAERS | |
| 42 | Unevaluable event | FAERS: 1 | US FAERS | |
| 43 | Wheezing | FAERS: 1 | US FAERS | |
| 44 | treatment failure | FAERS: 1 | US FAERS | |
| 45 | Ataxia | 28842171 | CTD | |
| 46 | Blepharitis | Canada Vigilance: 1 | Canada Vigilance | |
| 47 | Conjunctivitis | Canada Vigilance: 1 | Canada Vigilance | |
| 48 | Dermatitis | Canada Vigilance: 2 | Canada Vigilance | |
| 49 | Erythema Multiforme | Canada Vigilance: 1 | Canada Vigilance | |
| 50 | Erythema | Canada Vigilance: 2 | Canada Vigilance | |
| 51 | Headache | Canada Vigilance: 2 | Canada Vigilance | |
| 52 | Hypersensitivity | Canada Vigilance: 1 | Canada Vigilance | |
| 53 | Muscle Weakness | 28842171 | CTD | |
| 54 | Nausea | Canada Vigilance: 2 | Canada Vigilance | |
| 55 | Paresthesia | 28842171 | CTD | |
| 56 | Rash erythematous | Canada Vigilance: 1 | Canada Vigilance | |
| 57 | Urticaria | Canada Vigilance: 2 | Canada Vigilance | |
| 58 | Visual Impairment | Canada Vigilance: 1 | Canada Vigilance | |
| 59 | Vomiting | Canada Vigilance: 1 | Canada Vigilance |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120295
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.